Overview and Scope
Hematocrit test devices refer to medical instruments used to measure the percentage of red blood cells (RBCs) in a person’s total blood volume. These devices are utilized for monitoring chronic conditions, preoperative assessments, detecting blood doping, screening blood donors, managing emergencies, and conducting research and clinical trials.
Sizing and Forecast
The hematocrit test devices market size has grown strongly in recent years. It will grow from $4.35 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to a rise in awareness regarding anemia, lack of iron and vitamins, increased incidence of chronic illnesses, the surge in government funding, and increase in the population.
The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $5.98 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing prevalence of anemia, growing cases of blood disorders, rise in geriatric population, growth in focus on health and fitness, and widening need for cardiovascular diagnostic equipment. Major trends in the forecast period include the introduction of cutting-edge solutions, advancement of technology in medical science, creation of new efficient and innovative products, technical developments in hematocrit testing, and advancements in the healthcare sector.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report
Segmentation & Regional Insights
The hematocrit test devices market covered in this report is segmented –
1) By Product: Hematocrit Test Meter, Hematocrit Test Analyzer, Reagents And Consumables
2) By Application: Anemia, Polycythemia Vera, Congenital Heart Diseases, Other Applications
3) By End-User: Hospitals And Ambulatory Surgical Centers, Clinics, Diagnostic And Pathology Labs, Other End-Users
North America was the largest region in the hematocrit test devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=15582&type=smp
Major Driver Impacting Market Growth
The growing cases of blood disorders are expected to propel the growth of the hematocrit test devices market going forward. A blood disorder is a condition that affects the components of human blood, including red blood cells, white blood cells, platelets, and blood plasma. Blood disorders are becoming more common due to several variables, including genetic predispositions, pollution in the environment, and lifestyle changes. Hematocrit test devices are primarily used to measure the volume percentage of red blood cells in whole blood, providing crucial information about the patient’s hematological health. For instance, in January 2024, according to a report published by the American Cancer Society, a US-based non-profit organization, approximately 62,770 new cases of leukemia, encompassing all types, are anticipated in the United States in 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, primarily affecting adults, with approximately 11,220 deaths attributed to AML, almost exclusively occurring in adult patients. Therefore, the growing cases of blood disorders are driving the growth of the hematocrit test devices market.
Key Industry Players
Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton, Dickinson and Company (BD), Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, Heska Corporation, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory Lp, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.
The hematocrit test devices market report table of contents includes:
1. Executive Summary
2. Hematocrit Test Devices Market Characteristics
3. Hematocrit Test Devices Market Trends And Strategies
4. Hematocrit Test Devices Market – Macro Economic Scenario
5. Global Hematocrit Test Devices Market Size and Growth
.
.
.
31. Hematocrit Test Devices Market Other Major And Innovative Companies
32. Global Hematocrit Test Devices Market Competitive Benchmarking
33. Global Hematocrit Test Devices Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Hematocrit Test Devices Market
35. Hematocrit Test Devices Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
